Ebru SARI, Gökşen İnanç İMAMOĞLU, Dilşen ÇOLAK, Naziyet KÖSE, Mustafa ALTINBAŞ

Kemoterapi Öncesi Uygulanan Premedikasyondaki Gelişmeler

Son yirmi yılda elde edilen gelişmelere rağmen, bulantı ve özellikle kusma, kanser kemoterapisinin en sıkıntılı iki yanetkisi olamaya devam etmektedir. 1990lı yılların sonlarında birçok profesyonel kuruluş kemoterapi ve radyoterapiuygulanacak hastalara yönelik uygun antiemetik proflaksi için öneriler yayınlamışlardır. Bulantının yanı sıra, sisplatinaracılı gecikmiş bulantı kusmada antiemetik tedavi, yüksek doz kemoterapiye bağlı bulantı ve kusma tedavisi, kom- bine kemoradyoterapi ilişkili bulantı ve kusmada tedavi ile çocuklarda kullanılacak antiemetiklerin neler olacağı gibiek sorunlar da karşımıza çıkmaktadır. Bu nedenle, bu konular üzerinde daha fazla araştırmaya ihtiyaç bulunmaktadır.Yeni antiemetiklerin geliştirilmesi ile kemoterapi ve/veya radyoterapi gören hastaların yaşam kalitesi de artacaktır.

Developments In Premedication Administered Before Chemotherapy

Despite the relevant progress achieved in the last 20 years, vomiting and, especially, nausea, continue to be two of themost distressing side-effects of cancer chemotherapy. In the late 1990s several professional organizations publishedrecommendations on the optimal antiemetic prophylaxis in patients submitted to chemotherapy and radiotherapy. Be- sides nausea, additional problems of antiemetic therapy such as prophylaxis of cisplatin-induced delayed nausea andvomiting, nausea and vomiting induced by high-dose chemotherapy and nausea and vomiting induced by combined chemoradiation as well as antiemetics in children remain unsolved. Therefore, more research on these topics is neces- sary as is the development of new antiemetics, thereby leading to an improvement in quality of life in patients treatedwith chemotherapy and/or radiotherapy.

PDF

___

1. Markmann M et.al. Progress in preventing chemotherapy-induced nausea and vomiting. J Clin Oncol 1999;17: 1441.
2. Gadducci A, Tana R, Teti G, et al. Analysis of the pattern of hyper- sensitivity reactions in patients receiving carboplatin retreatment for recurrent ovarian cancer. Int J Gynecol Cancer 2008;18: 615- 20.
3. Polyzos A,Tsavaris N,Gogas H,Souglakos J,Vambakas L,Vardakas N,Polyzos K,Tsigris C,Mantas D,Papachristodoulou A,Nikiteas N,Karavokyros J.G,Felekouras E, Griniatsos J,Giannopoulos A,Kouraklis G. Clinical Features of Hypersensitivity Reactions to Oxaliplatin: A 10-Year Experience Oncology 2009;76: 3641.
4. Suenaga M, Mizunuma N, Shinozaki E, et al. Management of al- lergic reactions to oxaliplatin in colorectal cancer patients. J Sup- port Oncol. 2008;6: 3738.
5. Leguy-Seguin V, Jolimoy G, Coudert B, Pernot C, Dalac S, Vab- res P, Collet E etçal. Diagnostic and predictive value of skin testing in platinum salt hypersensitivity. J Allergy Clin Immunol 2007; 119:726-30.
6. Mariana C Castells, MD, PhDUrsula A Matulonis, MD. Infu- sion reactions to systemic chemotherapy. Allergy Asthma Proc 2011;32: 79.
7. Syrigou E et al. Hypersensitivity reactions to docetaxel: retrospec- tive evaluation and development of a desensitization protocol. Int Arch Allergy İmmunol 2011;156:3200.
8. Weiss RB, Donehower RC, Wiernik PH, et al: Hypersensitivity re- actions from taxol. J Clin Oncol 8:1263-1268, 1990.
9. Bookman MA, Kloth DD, Kover PE, et al. Short-course intrave- nous prophylaxis for paclitaxel-related hypersensitivity reactions. Ann Oncol 8:611-614, 1997.
10. Markman M, Kennedy A, Webster K, et al. An effective and more convenient drug regimen for prophylaxis against paclitaxel- associated hypersensitivity reactions. J Cancer Res Clin Oncol 125:427-429, 1999.
11. Micha JP, Rettenmaier MA, Dillman R, et al. Single-dose dexa- methasone paclitaxel premedication. Gynecol Oncol 69:122-124, 1998.
12. lmanell Jell et al. Systemic Therapy Emergencies. Semin Oncol 2000;27:347.
13. Maurie Markman, Alexander Kennedy, Kenneth Webster, Paul El- son, Gertrude Peterson. Clinical Features of Hypersensitivity Re- actions to Carboplatin. J Clin Oncol 17:1141-1145.
14. Barbara Kulp and Jerome Belinson. Paclitaxel-Associated Hyper- sensitivity Reactions: Experience of the Gynecologic Oncology Program of the Cleveland Clinic Cancer Center. J Clin Oncol 18:102-105.
15. Burris HA et al. Optimal use of docetaxel (Taxotere): Maximizing its potential. Anticancer Drugs 1996;7 suppl 2:25-28.
16. National Comprehensive Cancer Net¬work. NCCN Clinical Prac- tice Guidelines in Oncology; v.1.2007: Antiemesis.
17. Morran C, Smith DC, Anderson DA, McArdle CS. Incidence of na- usea and vomit¬ing with cytotoxic chemotherapy: a prospec¬tive randomised trial of antiemetics. Br Med J 1979;1:13231324.
18. Cohen L, de Moor CA, Eisenberg P, Ming EE, Hu H. Chemotherapy-induced nausea and vomitingincidence and im- pact on patient quality of life at community oncol¬ogy settings. Support Care Cancer 2006 Nov 14.
19. Bloechl-Daum B, Deuson RR, Mavros P, Hansen M, Herrstedt J. Delayed nausea and vomiting continue to reduce patients quality of life after highly and moderately emetogenic chemotherapy des- pite antiemet¬ic treatment. J Clin Oncol 2006;24:44724478.
20. Osoba D, Zee B, Warr D, Latreille J, Kaizer L, Pater J. Effect of postchemotherapy nausea and vomiting on health-related qual¬ity of life. The Quality of Life and Symptom Control Committees of the National Cancer Institute of Canada Clinical Trials Group. Support Care Cancer 1997;5:307313.
21. Gralla RJ, de Wit R, Herrstedt J, et al. Antiemetic efficacy of the neurokinin-1 an¬tagonist, aprepitant, plus a 5HT3 antago- nist and a corticosteroid in patients receiving an¬thracyclines or cyclophosphamide in addi¬tion to high-dose cisplatin: analysis of com¬bined data from two phase III randomized clinical trials. Cancer 2005;104:864868.
22. Lindley CM, Bernard S, Fields SM. Incidence and duration of chemotherapy-induced nausea and vomiting in the out¬patient on- cology population. J Clin Oncol 1989;7:11421149.
23. Richardson JL, Marks G, Levine A. The influence of symptoms of disease and side effects of treatment on compliance with cancer therapy. J Clin Oncol 1988;6:17461752.
24. Schwartzberg L. Chemotherapy-induced nausea and vomiting: state of the art in 2006. J Support Oncol 2006;4(2 suppl 1):38.
25. Grunberg SM, Osoba D, Hesketh PJ, et al. Evaluation of new an- tiemetic agents and definition of antineoplastic agent emetogeni- cityan update. Support Care Cancer 2005;13:8084.
26. Mitchell EP. Gastrointestinal toxic¬ity of chemotherapeutic agents. Semin Oncol 1992;19:566579.
27. Roila F, Hesketh PJ, Herrstedt J; An¬tiemetic Subcommittee of the Multinational Association of Supportive Care in Cancer. Preventi- on of chemotherapy- and radio¬therapy-induced emesis: results of the 2004 Perugia International Antiemetic Consensus Conference. Ann Oncol 2006;17:2028.
28. Kris MG, Hesketh PJ, Somerfield MR, et al. American Society of Clinical On¬cology guideline for antiemetics in oncology: update 2006. J Clin Oncol 2006;24:29322947.
29. Hesketh PJ, Kris MG, Grunberg SM, et al. Proposal for classif- ying the acute emetogenicity of cancer chemotherapy. J Clin On- col 1997;15:103109.
30. American Society of Clinical Guidelines (ASCO) version 1.2011 page 4189-4198.
31. Grunberg S, Chua D, Maru A et.al. Single-dose fosaprepitant for the prevention of chemotherapy induced nausea and vomitting as- sociated with cisplatin therapy : randomized double blind strudy protocol-EASE.J Clin Oncol 2011;29:1495-1501.
32. Warr DG, Hesketh PJ et.al. Efficacy and tolerability of aprepitant for the prevention of chemotherapy induced nausea and vomitting in patients with breast cancer after moderately emetogenic che- motherapy . J Support Oncol 2006;4:403-408.
33. Navari RM et.al. A phase 2 trial of olanzapine for the prevention of chemotherapy induced nausea and vomitting. Support Care Can- cer 2005;13:529-534.
34. National Comprehensive Cancer Network Guidelines (NCCN) Antiemesis: version 1. 2013 page 5-31.
35. De Leon A. Palonosetron (Aloxi): a second-generation 5-HT(3) re- ceptor an¬ De Leon A. Palonosetron (Aloxi): a second-generation 5-HT(3) receptor an¬tagonist for chemotherapy-induced nausea and vomiting. Proc (Bayl Univ Med Cent) 2006;19:413416.
36. Del Giglio A, Soares HP, Caparroz C, Castro PC. Granisetron is equivalent to on¬dansetron for prophylaxis of chemotherapy- induced nausea and vomiting: results of a meta-analysis of rando- mized controlled trials. Cancer 2000;89:23012308.
37. Hamadani M, Awab A, Chaudhary L, Tfayli A. Relative efficacy of ondansetron, granisetron, dolasetron and palonosetron in control- ling acute nausea and vomiting asso¬ciated with platinum-based chemotherapy. J Oncol Pharm Pract 2006;12:6768.
38. Gralla R, Lichinitser M, Van Der Vegt S, et al. Palonosetron imp- roves preven¬tion of chemotherapy-induced nausea and vomi- ting following moderately emetogen¬ic chemotherapy: results of a double-blind randomized phase III trial comparing sin¬gle do- ses of palonosetron with ondansetron. Ann Oncol 2003;14:1570 1577.
39. Aapro MS, Grunberg SM, Manikhas GM, et al. A phase III, double-blind, ran¬domized trial of palonosetron compared with ondansetron in preventing chemother¬apy-induced nausea and vo- miting following highly emetogenic chemotherapy. Ann On¬col 2006;17:14411449.
40. United States Food and Drug Administration. Anzemet (dolaset- ron mesylate) :Drug Safety Communication-Reports of Abnormal Hearth Rhytms.2010.
41. European Society for Medical Oncology Guidelines (ESMO) ver- sion 1.2010 page 232-243 .
42. Morrow GR, Morrell C. Behavioral treatment for the anticipatory nausea and vomiting induced by cancer chemotherapy. N Engl J Med 1982;307:14761480.
43. Ezzo J, Vickers A, Richardson MA, et al. Acupuncture-point sti- mulation for chemotherapy-induced nausea and vomit¬ing. J Clin Oncol 2005;23:71887198.
44. Redd WH, Andrykowski MA. Be¬havioral intervention in can- cer treatment: controlling aversion reactions to chemother¬apy. J Consult Clin Psychol 1982;50:10181029.
45. NECN Guidelines for the Management of Chemotherapy and Systemic Anticancer Therapy Induced Toxicities Within Primary Care v1.2, page 8-11.